 CAMBRIDGE, Mass., Sept. 07, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will present an update on Company progress at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7:00AM E.T. using a virtual platform. 